Outcomes12

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 12 of 12

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression Free Survival at 12 Weeks for Patients With Soft Tissue Sarcoma (STS) Treated With Pazopanib and Oral Topotecan	At 12 weeks from treatment initiation	Only patients with soft tissue sarcoma were eligible for this endpoint. 105 patients enrolled in this trial had soft tissue sarcoma. 1 patient of these 105 was found not to be evaluable.	percentage of patients progression free	NUMBER
SECONDARY	Overall Response Rate (ORR) for Patients With Soft Tissue Sarcoma (STS) Treated With Combination Pazopanib and Topotecan.	During treatment, assessed at 6 weeks, 12 weeks, 20 weeks and then every 2 cycles where one cycle = 28 days and range of cycles completed by patients 1-33.	Patients with Soft Tissue Sarcoma treated on study eligible for this endpoint, even if there are major protocol treatment deviations or patients exhibit objective disease progression prior to the end of cycle 1.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Clinical Benefit Rate (CBR) for Patients With Soft Tissue Sarcoma (STS) Treated With Combination Pazopanib and Topotecan.	During treatment, assessed at 6 weeks, 12 weeks, 20 weeks and then every 2 cycles where one cycle = 28 days and range of cycles completed by patients 1-33.	Patients with Soft Tissue Sarcoma treated on study eligible for this endpoint, even if there are major protocol treatment deviations or patients exhibit objective disease progression prior to the end of cycle 1.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Overall Survival (OS) for Patients With Soft Tissue Sarcoma (STS) Treated With Combination Pazopanib and Topotecan.	During treatment where one cycle = 28 days and range of cycles completed by patients 1-33, then for 2 years (for patients with progression) and 5 years (for patients without progression) following discontinuation of treatment	Only patients with soft tissue sarcoma were eligible for this endpoint. 105 patients enrolled in this trial had soft tissue sarcoma. 1 patient of these 105 was found not to be evaluable.	months	MEDIAN
SECONDARY	Number of Patients With Significant Adverse Events, Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03	From treatment initiation until 30 days post last treatment, at the beginning of each cycle where 1 cycle=28 days. Range of cycles completed by patients 1-33 cycles		patients	NUMBER
SECONDARY	Median Progression Free Survival (PFS) for Patients With Soft Tissue Sarcoma (STS) Treated With Combination Pazopanib and Topotecan.	During treatment, assessed at 6 weeks, 12 weeks, 20 weeks and then every 2 cycles where one cycle = 28 days and range of cycles completed by patients 1-33. And then for up to 5 years post treatment discontinuation.	Only patients with soft tissue sarcoma were eligible for this endpoint. 105 patients enrolled in this trial had soft tissue sarcoma. 1 patient of these 105 was found not to be evaluable.	months	MEDIAN
SECONDARY	Progression Free Survival in Patients With Osteosarcoma Treated With Combination Pazopanib and Topotecan.	During treatment, assessed at 6 weeks, 12 weeks, 20 weeks and then every 2 cycles where one cycle = 28 days and range of cycles completed by patients 1-33. Then for up to 5 years post treatment discontinuation	Only patients with Osteosarcoma were eligible for this endpoint.	months	MEDIAN
SECONDARY	Progression Free Survival for Patients With Liposarcoma Treated With Combination Pazopanib and Topotecan.	During treatment, assessed at 6 weeks, 12 weeks, 20 weeks and then every 2 cycles where one cycle = 28 days and range of cycles completed by patients 1-33. Then up to 5 years post treatment discontinuation.	Patients with liposarcoma were eligible for this endpoint.	Months	MEDIAN
OTHER_PRE_SPECIFIED	Change in Cytokine Levels	Baseline to 12 weeks
POST_HOC	Overall Survival of Patients With Liposarcoma Treated With With Pazopanib and Oral Topotecan Combination	During treatment, where one cycle = 28 days and range of cycles completed by patients 1-33. Then for up to 5 years post treatment discontinuation.	At the time of the calculation, 12 events were seen out of a possible 16.	Weeks	MEDIAN
POST_HOC	Duration of Best Response in Patients With Soft Tissue Sarcoma Treated With Pazopanib and Topotecan Combination	From time of initial response until progressive disease, up to 60 weeks.	At time of analysis 66 events were seen out of the possible 68.	Weeks	MEDIAN
POST_HOC	Duration of Best Response in Patients With Liposarcoma Treated With Pazopanib and Topotecan Combination	From time of initial response until progressive disease, up to 60 weeks.	At the time of the analysis 7 events were seen out of a possible 8.	Weeks	MEDIAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02357810/outcomes

API reference For AI assistants